Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Content Channel
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
Angus Liu
May 27, 2026 11:25am
Novo's Indiana plant claims another victim in Incyte's PD-1
Mar 9, 2026 10:45am
Padcev-Keytruda combo wins in MIBC amid evolving landscape
Feb 27, 2026 10:00am
GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
Jan 20, 2026 2:26pm
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
